×
About 1,193 results

ALLMedicine™ Hepatorenal Syndrome Center

Research & Reviews  399 results

Extrahepatic causes of death in cirrhosis compared to other chronic conditions in the U...
https://doi.org/10.1016/j.aohep.2021.100565
Annals of Hepatology; Shankar N, Ramani A et. al.

Nov 4th, 2021 - Cirrhosis-related mortality is underestimated and is increasing; extrahepatic factors may contribute. We examined trends in cirrhosis mortality from 1999-2017 in the United States attributed to liver-related (varices, peritonitis, hepatorenal synd...

Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis
https://clinicaltrials.gov/ct2/show/NCT01809132

Nov 1st, 2021 - This study will test the hypothesis that the syndrome of acute alcoholic hepatitis results from severe inflammation and dysregulated cytokines. Steroid monotherapy is not effective in all patients and this study will utilize compounds that have th...

Improvement of renal function prior to liver transplantation is not associated with bet...
https://doi.org/10.1016/j.aohep.2021.100559
Annals of Hepatology; Horvatits T, Hübener P et. al.

Oct 18th, 2021 - Since MELD implementation renal impairment in liver transplant (LT) recipients has become of increasing importance. This is the first study evaluating the course of renal function immediately prior to LT as predictor for long-term renal and overal...

Mac-2 binding protein glycosylation isomer is a potential biomarker to predict portal h...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516253
PloS One; Wu PS, Hsieh YC et. al.

Oct 15th, 2021 - Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel plasma biomarker for liver fibrosis, but less is known about its role in portal hypertension. We aimed to evaluate the association between M2BPGi and hepatic venous pressure gradient (...

Higher Mean Corpuscular Hemoglobin Concentration is Associated with Worse Prognosis of ...
https://doi.org/10.1016/j.amjms.2021.06.026
The American Journal of the Medical Sciences; Sheng X, Chen W et. al.

Oct 9th, 2021 - Hepatorenal syndrome (HRS) is a severe complication of decompensated cirrhosis with high mortality. However, few prognostic factors have been identified and studies are urgently needed to facilitate precise treatment. Patients with decompensated c...

see more →

Clinicaltrials.gov  30 results

Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis
https://clinicaltrials.gov/ct2/show/NCT01809132

Nov 1st, 2021 - This study will test the hypothesis that the syndrome of acute alcoholic hepatitis results from severe inflammation and dysregulated cytokines. Steroid monotherapy is not effective in all patients and this study will utilize compounds that have th...

Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903)
https://clinicaltrials.gov/ct2/show/NCT04028323

Aug 17th, 2021 - Gastroesophageal varices, the most relevant portal-system collaterals, and acute variceal bleeding are critical complications that result directly from portal hypertension in patients with cirrhosis. Gastroesophageal varices are present approximat...

MRI to Assess the Effect of Terlipressin in Patients With Acute Hepatorenal Syndrome (HRS-AKI)
https://clinicaltrials.gov/ct2/show/NCT03483272

Aug 16th, 2021 - Heptorenal syndrome (HRS) is divided into two types. A non-acute kidney injury (NAKI-HRS), which is predominantly related to end-stage disease and a more acute kidney injury (HRS-AKI). HRS-AKI is potentially reversible and develops subsequent to a...

Non-invasive Evaluation of the Predictive Value of CEUS and SWE in ACLF, Renal Failure and Hepatorenal Syndrome
https://clinicaltrials.gov/ct2/show/NCT04446858

Apr 28th, 2021 - NECTAR consists of patients with ACLF and renal failure with and without receiving transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Internal Medicine I, University of Bonn, Germany and receiving a structured routine evalua...

Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey
https://clinicaltrials.gov/ct2/show/NCT04121520

Feb 24th, 2021 - Portal hypertension is an important factor affecting the clinical outcomes of cirrhosis patients, and its severity determines the occurrence of development of cirrhosis complications, such as rupture and bleeding of gastroesophageal varices, ascit...

see more →

News  48 results

Terlipressin Shows Benefit in Hepatorenal Syndrome but Risks Spark Concern
https://www.medscape.com/viewarticle/946833

Mar 4th, 2021 - NEW YORK (Reuters Health) - Details of the phase-3 CONFIRM trial show the vasopressin analog terlipressin can reverse the effects of type 1 hepatorenal syndrome (HRS-1), although not without potentially serious side effects. The study, published i...

Axitinib/Octreotide Combo Fails to Improve PFS in Pancreatic NETs
https://www.onclive.com/view/axitinib-octreotide-combo-fails-to-improve-pfs-in-pancreatic-nets

Jan 17th, 2021 - Axitinib (Inlyta) plus octreotide LAR failed to demonstrate a significant improvement in progression-free survival (PFS) compared with placebo plus octreotide LAR in patients with advanced G1-2 extra-pancreatic neuroendocrine tumors (NETs), accord...

Cabozantinib Improves OS, PFS in Advanced HCC
https://www.onclive.com/view/cabozantinib-improves-os-pfs-for-advanced-hcc

Dec 20th, 2020 - Ghassan Abou-Alfa, MD Treatment with cabozantinib (Cabometyx) improved median overall survival (OS) by 2.2 months compared with placebo for patients with previously treated advanced hepatocellular carcinoma (HCC), according to findings from the p...

Cabozantinib Approved in Japan for Advanced Hepatocellular Carcinoma
https://www.onclive.com/view/cabozantinib-approved-in-japan-for-advanced-hepatocellular-carcinoma

Nov 30th, 2020 - The Japanese Ministry of Health, Labor, and Welfare has approved cabozantinib (Cabometyx) for the treatment of patients with unresectable hepatocellular carcinoma (HCC) that has progressed on prior systemic therapy.1 The approval is based on resu...

Terlipressin Squeaks by FDA Review for Hepatorenal Syndrome 1
https://www.staging.medscape.com/viewarticle/934042

Jul 16th, 2020 - The US Food and Drug Administration's (FDA's) Cardiovascular and Renal Drugs Advisory Committee narrowly recommended, by an 8-7 vote, that the agency grant marketing approval to terlipressin for the treatment of hepatorenal syndrome type 1, a seve...

see more →